What is Lifesci Capital's Estimate for AVDL Q2 Earnings?

Avadel Pharmaceuticals plc (NASDAQ:AVDL - Free Report) - Stock analysts at Lifesci Capital issued their Q2 2025 EPS estimates for Avadel Pharmaceuticals in a research note issued on Monday, March 3rd. Lifesci Capital analyst M. Belghiti forecasts that the company will post earnings of $0.02 per share for the quarter. The consensus estimate for Avadel Pharmaceuticals' current full-year earnings is ($0.51) per share.

Other analysts have also recently issued research reports about the stock. Piper Sandler reduced their price objective on shares of Avadel Pharmaceuticals from $24.00 to $13.00 and set an "overweight" rating on the stock in a research note on Friday, January 10th. Deutsche Bank Aktiengesellschaft assumed coverage on Avadel Pharmaceuticals in a research note on Tuesday, February 11th. They issued a "buy" rating and a $12.00 price objective on the stock. UBS Group decreased their target price on shares of Avadel Pharmaceuticals from $22.00 to $14.00 and set a "buy" rating for the company in a research report on Monday, January 13th. HC Wainwright restated a "buy" rating and issued a $21.00 price target on shares of Avadel Pharmaceuticals in a research report on Tuesday, March 4th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $19.00 price objective on shares of Avadel Pharmaceuticals in a research report on Monday, March 3rd. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $19.88.

Remove Ads

Avadel Pharmaceuticals Stock Performance

Shares of NASDAQ:AVDL traded down $0.30 during midday trading on Thursday, hitting $7.61. 1,250,424 shares of the stock were exchanged, compared to its average volume of 1,185,411. Avadel Pharmaceuticals has a 12 month low of $7.39 and a 12 month high of $19.09. The business's 50-day moving average price is $8.57 and its 200 day moving average price is $11.30. The stock has a market capitalization of $733.31 million, a price-to-earnings ratio of -9.63 and a beta of 1.57.

Insider Buying and Selling

In other news, Director Linda Palczuk bought 5,000 shares of Avadel Pharmaceuticals stock in a transaction dated Tuesday, January 21st. The stock was purchased at an average price of $7.93 per share, for a total transaction of $39,650.00. Following the purchase, the director now directly owns 67,900 shares in the company, valued at $538,447. The trade was a 7.95 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Peter J. Thornton purchased 10,000 shares of the company's stock in a transaction that occurred on Monday, January 13th. The shares were purchased at an average cost of $8.04 per share, for a total transaction of $80,400.00. Following the completion of the transaction, the director now directly owns 104,055 shares of the company's stock, valued at $836,602.20. This represents a 10.63 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 42,579 shares of company stock worth $396,057 in the last ninety days. Corporate insiders own 4.80% of the company's stock.

Institutional Trading of Avadel Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of AVDL. FMR LLC purchased a new stake in shares of Avadel Pharmaceuticals during the 3rd quarter valued at $31,000. Advisors Asset Management Inc. raised its position in Avadel Pharmaceuticals by 56.1% in the third quarter. Advisors Asset Management Inc. now owns 7,921 shares of the company's stock worth $104,000 after acquiring an additional 2,846 shares during the period. Hsbc Holdings PLC purchased a new position in Avadel Pharmaceuticals in the fourth quarter valued at about $113,000. Kazazian Asset Management LLC bought a new position in shares of Avadel Pharmaceuticals during the 4th quarter valued at approximately $126,000. Finally, Sanctuary Advisors LLC purchased a new stake in shares of Avadel Pharmaceuticals during the 4th quarter worth approximately $140,000. 69.19% of the stock is owned by hedge funds and other institutional investors.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.